

# Ulrich Specks

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5534550/publications.pdf>

Version: 2024-02-01

245  
papers

18,928  
citations

12303

69  
h-index

12910

131  
g-index

252  
all docs

252  
docs citations

252  
times ranked

9990  
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1710-1721.	0.4	25
2	Vasculitis and Alveolar Hemorrhage. , 2022, , 341-357.		0
3	Hypothyroidism in vasculitis. <i>Rheumatology</i> , 2022, 61, 2942-2950.	0.9	2
4	Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with <scp>ANCA-associated</scp> Vasculitis. <i>ACR Open Rheumatology</i> , 2022, 4, 168-176.	0.9	6
5	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. <i>Clinical Pharmacokinetics</i> , 2022, 61, 423-437.	1.6	5
6	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 834981.	2.2	19
7	Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1033-1044.	3.0	47
8	Association of <scp>COVID</scp>-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis. <i>Respirology Case Reports</i> , 2022, 10, e0894.	0.3	13
9	Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1223-1224.	3.0	5
10	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	0.6	2
11	Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 64-72.	0.5	2
12	Improvement of constrictive bronchiolitis (bronchiolitis obliterans) after rituximab therapy in 2 patients with primary sjögren syndrome. <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101432.	0.2	1
13	The Survival of Patients With Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2021, 48, 314-317.	1.0	0
14	Clinical Manifestations and Long-term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	0.9	21
15	Interstitial Lung Disease and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Chest</i> , 2021, 159, 2141-2142.	0.4	3
16	Pleuritis and Pericarditis in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Chest</i> , 2021, 160, 572-581.	0.4	8
17	Plasma exchange for the management of ANCA-associated vasculitis: the con position. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 231-236.	0.4	12
18	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. <i>JCI Insight</i> , 2021, 6, .	2.3	7

#	ARTICLE	IF	CITATIONS
19	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 114-118.	0.4	3
20	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 114-118.	0.4	14
21	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 283-291.	0.4	40
22	Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. <i>Clinical Pharmacokinetics</i> , 2020, 59, 519-530.	1.6	12
23	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1001-1010.	1.0	20
24	Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis: clinical presentation and antineutrophil cytoplasmic antibodies. <i>International Forum of Allergy and Rhinology</i> , 2020, 10, 217-222.	1.5	8
25	Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. <i>Clinical Rheumatology</i> , 2020, 39, 1581-1590.	1.0	16
26	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	2.5	79
27	ANCA-associated vasculitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 71.	18.1	443
28	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. <i>Frontiers in Immunology</i> , 2020, 11, 2053.	2.2	12
29	Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2688-2704.	3.0	48
30	Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply. <i>Rheumatology</i> , 2020, 59, 1187-1187.	0.9	0
31	Lung involvement in ANCA-associated vasculitis. <i>Presse Medicale</i> , 2020, 49, 104039.	0.8	33
32	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.5	93
33	International Consensus on Antineutrophil Cytoplasmic Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1360-1372.	2.5	36
34	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020, 382, 622-631.	13.9	465
35	Eosinophilic Granulomatosis With Polyangiitis. <i>Chest</i> , 2020, 157, 1086-1099.	0.4	26
36	Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features. <i>American Journal of Pathology</i> , 2020, 190, 1438-1448.	1.9	7

#	ARTICLE	IF	CITATIONS
37	Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. <i>JCI Insight</i> , 2020, 5, .	2.3	6
38	Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1508-1517.	0.4	46
39	Update on the Management of Respiratory Manifestations of the Antineutrophil Cytoplasmic Antibodies-Associated Vasculitides. <i>Clinics in Chest Medicine</i> , 2019, 40, 573-582.	0.8	19
40	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Autoimmunity</i> , 2019, 105, 102302.	3.0	24
41	The Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 1243-1243.	1.0	3
42	Remote Activation of a Latent Epitope in an Autoantigen Decoded With Simulated B-Factors. <i>Frontiers in Immunology</i> , 2019, 10, 2467.	2.2	7
43	172. THE ASSOCIATION OF DIFFERENCES IN LIPID PARAMETERS WITH DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS (AAV). <i>Rheumatology</i> , 2019, 58, .	0.9	0
44	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Randomized Controlled Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 952-963.	2.9	82
45	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2170-2177.	1.5	82
46	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1888-1893.	2.9	25
47	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1879-1887.	2.9	23
48	Exostosin 1/Exostosin 2-associated Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1123-1136.	3.0	198
49	053. CLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
50	Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. <i>Rheumatology</i> , 2019, 58, 1707-1709.	0.9	32
51	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	1.0	6
52	THU0309...NONLINEAR PHARMACOKINETICS OF RITUXIMAB IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS. , 2019, , .		0
53	SAT0012...DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS. , 2019, , .		0
54	SAT0236...RELATIONSHIP BETWEEN RITUXIMAB CONCENTRATION AND AUTOANTIBODY LEVELS IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	Remission maintenance in ANCA-associated vasculitis: does one size fit all?. Expert Review of Clinical Immunology, 2019, 15, 1273-1286.	1.3	0
56	Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 40-44.	0.4	7
57	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis and Rheumatology, 2018, 70, 1114-1121.	2.9	49
58	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology, 2018, 57, 639-650.	0.9	20
59	The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 251-257.	2.2	50
60	Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study. Mayo Clinic Proceedings, 2018, 93, 597-606.	1.4	69
61	PREVALENCE OF PLEURITIS AND PERICARDITIS IN ANCA-ASSOCIATED VASCULITIS. Chest, 2018, 154, 1019A-1020A.	0.4	1
62	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. PLoS ONE, 2018, 13, e0205768.	1.1	6
63	Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2018, 70, 2077-2086.	2.9	12
64	Acquired cyclic neutropenia associated with cocaine-induced anti-neutrophil cytoplasmic antibodies binding to human neutrophil elastase. American Journal of Hematology, 2018, 93, E227-E229.	2.0	2
65	Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. Respiratory Medicine, 2018, 142, 66-72.	1.3	18
66	Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis. Clinical and Experimental Immunology, 2017, 188, 174-181.	1.1	12
67	Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn. Nephrology Dialysis Transplantation, 2017, 32, gfw384.	0.4	12
68	Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasmic antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials, 2017, 18, 112.	0.7	65
69	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine, 2017, 376, 1921-1932.	13.9	682
70	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrology Dialysis Transplantation, 2017, 32, i139-i145.	0.4	59
71	Reply. Arthritis and Rheumatology, 2017, 69, 1507-1508.	2.9	0
72	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 1054-1066.	2.9	130

#	ARTICLE	IF	CITATIONS
73	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78
74	Current and Future Treatment Options for Eosinophilic Granulomatosis With Polyangiitis. <i>Current Treatment Options in Rheumatology</i> , 2017, 3, 193-206.	0.6	5
75	The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota. <i>Arthritis and Rheumatology</i> , 2017, 69, 2338-2350.	2.9	126
76	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. <i>American Journal of Nephrology</i> , 2017, 46, 231-238.	1.4	15
77	Revised 2017 international consensus on testing of ANCA in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 683-692.	3.5	302
78	The Pharmacogenomic Association of Fc $\gamma$ 3 Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 169-175.	2.9	21
79	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 1004-1010.	1.5	11
80	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Associated Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 185-193.	2.9	45
81	Identification and phenotyping of circulating autoreactive proteinase 3-specific B cells in patients with PR3-ANCA associated vasculitis and healthy controls. <i>Journal of Autoimmunity</i> , 2017, 84, 122-131.	3.0	40
82	Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. <i>Journal of Renal Injury Prevention</i> , 2017, 6, 18-25.	0.6	32
83	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e50.	2.1	24
84	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 98-101.	0.4	3
85	Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. <i>Arthritis and Rheumatology</i> , 2016, 68, 1467-1476.	2.9	94
86	Reply. <i>Arthritis and Rheumatology</i> , 2016, 68, 2828-2829.	2.9	0
87	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. <i>Analytical Chemistry</i> , 2016, 88, 6317-6325.	3.2	24
88	ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. <i>Nature Reviews Rheumatology</i> , 2016, 12, 570-579.	3.5	219
89	Myeloperoxidase-Associated Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. <i>Arthritis and Rheumatology</i> , 2016, 68, 2945-2952.	2.9	75
90	Advances in Management of Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis. <i>Chest</i> , 2016, 150, 536A.	0.4	0

#	ARTICLE	IF	CITATIONS
91	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. <i>Arthritis and Rheumatology</i> , 2016, 68, 1700-1710.	2.9	132
92	Inhibitors and Antibody Fragments as Potential Anti-Inflammatory Therapeutics Targeting Neutrophil Proteinase 3 in Human Disease. <i>Pharmacological Reviews</i> , 2016, 68, 603-630.	7.1	30
93	Biopsy-proven pulmonary capillaritis: A retrospective study of aetiologies including an in-depth look at isolated pulmonary capillaritis. <i>Respirology</i> , 2016, 21, 734-738.	1.3	20
94	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1166-1169.	0.5	196
95	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	1.6	109
96	Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). <i>PLoS ONE</i> , 2015, 10, e0121737.	1.1	35
97	Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1083-1087.	0.4	13
98	Isolated Pauciimmune Pulmonary Capillaritis Successfully Treated With Rituximab. <i>Chest</i> , 2015, 147, e134-e136.	0.4	17
99	Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1922-1932.	2.9	116
100	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015, 26, 545-553.	1.0	371
101	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015, 42, 1209-1212.	1.0	87
102	Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , 2015, 59, 43-52.	3.0	6
103	Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis?. <i>Current Opinion in Rheumatology</i> , 2015, 27, 231-240.	2.0	8
104	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1081-1082.	0.4	1
105	Reply: Further Progress in Understanding Fibrosing Mediastinitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 768-768.	2.5	3
106	Accurate Relapse Prediction in ANCA-Associated Vasculitis—the Search for the Holy Grail. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 505-507.	3.0	21
107	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 976-985.	3.0	137
108	Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 535-544.	2.9	25



#	ARTICLE	IF	CITATIONS
109	Pituitary Dysfunction in Granulomatosis With Polyangiitis: The Mayo Clinic Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3988-3994.	1.8	68
110	Targeting B Lymphocytes in Progressive Fibrosing Mediastinitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1069-1071.	2.5	46
111	Primary Antiphospholipid Syndrome—Associated Diffuse Alveolar Hemorrhage. <i>Arthritis Care and Research</i> , 2014, 66, 301-310.	1.5	47
112	Coexistent Pulmonary Granulomatosis With Polyangiitis (Wegener Granulomatosis) and Crohn Disease. <i>American Journal of Surgical Pathology</i> , 2014, 38, 354-359.	2.1	18
113	Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's). <i>Arthritis and Rheumatology</i> , 2014, 66, 428-432.	2.9	28
114	Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2014, 6, 58-74.	1.2	8
115	An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1376-1379.	0.5	128
116	Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 182-193.	0.6	6
117	Pathogenesis and Management of ANCA-Associated Vasculitis. , 2014, , 137-151.		0
118	Pulmonary Manifestations of Vasculitis. , 2014, , 123-137.		0
119	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2013, 369, 417-427.	13.9	611
120	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1342-1350.	0.5	109
121	Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener's). <i>Autoimmunity Reviews</i> , 2013, 12, 501-505.	2.5	60
122	S1. Rituximab for ANCA-associated vasculitis: The experience in the United States. <i>Presse Medicale</i> , 2013, 42, 530-532.	0.8	5
123	Association of Granulomatosis With Polyangiitis (Wegener's) With <i>HLA-DPB1*04</i> and <i>SEMA6A</i> Gene Variants: Evidence From Genome-Wide Analysis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2457-2468.	6.7	138
124	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2013, 40, 1905-1912.	1.0	40
125	Refining phenotypes in ANCA-associated vasculitis. <i>Nature Reviews Nephrology</i> , 2013, 9, 6-8.	4.1	5
126	A Monoclonal Antibody (MCPR3-7) Interfering with the Activity of Proteinase 3 by an Allosteric Mechanism. <i>Journal of Biological Chemistry</i> , 2013, 288, 26635-26648.	1.6	21



#	ARTICLE	IF	CITATIONS
127	Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2013, 40, 674-683.	1.0	39
128	Biologic response modifiers for granulomatosis with polyangiitis (Wegener's): from promise to reality. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 383-397.	0.3	0
129	Pneumocystis Pneumonia in Patients Treated With Rituximab. <i>Chest</i> , 2013, 144, 258-265.	0.4	154
130	Pulmonary Necrotizing Granulomas of Unknown Cause. <i>Chest</i> , 2013, 144, 813-824.	0.4	53
131	Will LAMP enlighten us about ANCA-associated vasculitis?. <i>Nature Reviews Nephrology</i> , 2012, 8, 318-320.	4.1	7
132	Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. <i>Current Opinion in Rheumatology</i> , 2012, 24, 15-23.	2.0	43
133	Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center. <i>Arthritis and Rheumatism</i> , 2012, 64, 3770-3778.	6.7	248
134	Pulmonary Vasculitis and Hemorrhage. , 2012, , 722-730.		0
135	Pathogenesis of ANCA-Associated Vasculitis. <i>Current Rheumatology Reports</i> , 2012, 14, 481-493.	2.1	77
136	Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3463-3471.	6.7	33
137	TNF-Blocker Therapy and Solid Malignancy Risk in ANCA-Associated Vasculitis. <i>Current Rheumatology Reports</i> , 2012, 14, 501-508.	2.1	9
138	Update on Diffuse Alveolar Hemorrhage and Pulmonary Vasculitis. <i>Immunology and Allergy Clinics of North America</i> , 2012, 32, 587-600.	0.7	75
139	Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis. <i>PLoS ONE</i> , 2012, 7, e30197.	1.1	16
140	Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2012, 64, 273-279.	1.5	49
141	Controversies in ANCA testing. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, S7-S11.	0.6	11
142	Biologic agents in the treatment of granulomatosis with polyangiitis. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, S50-S53.	0.6	6
143	Pulmonary Vasculitis. , 2012, , 365-386.		1
144	Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 704-704.	0.5	106

#	ARTICLE	IF	CITATIONS
145	Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegener's Granulomatosis. <i>Journal of Rheumatology</i> , 2011, 38, 1048-1054.	1.0	45
146	Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2865-2871.	0.4	92
147	The Growing Complexity of the Pathology Associated With Cocaine Use. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 167-168.	0.5	15
148	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multicenter Experience. <i>Transplantation</i> , 2011, 91, 1370-1375.	0.5	71
149	A Rare Cause Hemoptysis Illustrating the Role of Single Ventricle Physiology in Bronchial Circulation. <i>Chest</i> , 2011, 140, 83A.	0.4	1
150	Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2011, 63, 1777-1781.	1.5	60
151	Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): Long-term followup of a multicenter longitudinal cohort. <i>Arthritis and Rheumatism</i> , 2011, 63, 2495-2503.	6.7	58
152	Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3988-3997.	6.7	59
153	IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 20736-20741.	3.3	74
154	Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial. <i>Open Arthritis Journal</i> , 2011, 4, 1-18.	0.0	17
155	Alpha <sub>1</sub> -antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2010, 62, 3760-3767.	6.7	87
156	Mycophenolate Mofetil for Induction and Maintenance of Remission in Microscopic Polyangiitis with Mild to Moderate Renal Involvement: A Prospective, Open-Label Pilot Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 445-453.	2.2	89
157	Accuracy of the ICD-9 Code for Identification of Patients with Wegener's Granulomatosis: Table 1. <i>Journal of Rheumatology</i> , 2010, 37, 474-474.	1.0	11
158	Rituximab Therapy in Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2188-2198.	2.2	247
159	Mapping of Conformational Epitopes on Human Proteinase 3, the Autoantigen of Wegener's Granulomatosis. <i>Journal of Immunology</i> , 2010, 185, 387-399.	0.4	31
160	Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen. <i>Journal of Autoimmunity</i> , 2010, 35, 299-308.	3.0	35
161	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2010, 363, 221-232.	13.9	2,275
162	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1744-1750.	0.5	139

#	ARTICLE	IF	CITATIONS
163	Successful Pregnancy and Delivery of a Healthy Newborn Despite Transplacental Transfer of Antimyeloperoxidase Antibodies From a Mother With Microscopic Polyangiitis. <i>American Journal of Kidney Diseases</i> , 2009, 54, 542-545.	2.1	52
164	Epitope-specific anti-neutrophil cytoplasmic antibodies: Do they matter? Can they be detected?. <i>Apmis</i> , 2009, 117, 63-66.	0.9	6
165	ANCA-Associated Vasculitis. , 2009, , 245-267.		0
166	Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions. <i>Arthritis and Rheumatism</i> , 2008, 58, 1546-1551.	6.7	53
167	55-Year-Old Man With Purpura and Foot Pain. <i>Mayo Clinic Proceedings</i> , 2008, 83, 93-96.	1.4	0
168	Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 905-919.	2.2	126
169	Response to Rituximab in membranous nephropathy™. <i>Kidney International</i> , 2008, 74, 392.	2.6	0
170	Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. <i>Journal of Rheumatology</i> , 2008, 35, 2017-23.	1.0	78
171	Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis. <i>Annals of Internal Medicine</i> , 2007, 147, 611.	2.0	234
172	A REVIEW OF NECROTIZING GRANULOMAS. <i>Chest</i> , 2007, 132, 639A.	0.4	0
173	Outcome of Patients With Small-Vessel Vasculitis Admitted to a Medical ICU. <i>Chest</i> , 2007, 131, 972-976.	0.4	62
174	ANCA Are Detectable in Nearly All Patients with Active Severe Wegener™s Granulomatosis. <i>American Journal of Medicine</i> , 2007, 120, 643.e9-643.e14.	0.6	228
175	Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 741-754.	0.8	12
176	Airway Involvement in Wegener's Granulomatosis. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 755-775.	0.8	83
177	Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations. <i>Journal of Rheumatology</i> , 2007, 34, 1027-31.	1.0	22
178	The future of damage assessment in vasculitis. <i>Journal of Rheumatology</i> , 2007, 34, 1357-71.	1.0	33
179	The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. <i>Journal of Rheumatology</i> , 2007, 34, 2446-50.	1.0	35
180	Subtle modifications of a PR3-ANCA ELISA affect assay performance. <i>Clinical Immunology</i> , 2006, 118, 124-125.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Rituximab in Refractory Wegener's Granulomatosis: Favorable or Not?. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 816-816.	2.5	9
182	Solid malignancies among patients in the Wegener's granulomatosis etanercept trial. Arthritis and Rheumatism, 2006, 54, 1608-1618.	6.7	195
183	Rituximab for Refractory Wegener's Granulomatosis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 180-187.	2.5	379
184	Melanoma Antigen A4 Is Expressed in Non-“Small Cell Lung Cancers and Promotes Apoptosis. Cancer Research, 2006, 66, 4693-4700.	0.4	73
185	Functional Significance of Asn-linked Glycosylation of Proteinase 3 for Enzymatic Activity, Processing, Targeting, and Recognition by Anti-neutrophil Cytoplasmic Antibodies. Journal of Biochemistry, 2006, 141, 101-112.	0.9	16
186	Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Annals of Internal Medicine, 2005, 142, 620.	2.0	277
187	A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases. Journal of Immunological Methods, 2005, 307, 62-72.	0.6	23
188	Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and Rheumatism, 2005, 52, 262-268.	6.7	423
189	A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. Arthritis and Rheumatism, 2005, 52, 902-910.	6.7	43
190	Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism, 2005, 52, 2168-2178.	6.7	171
191	Methotrexate for Wegener's granulomatosis: What is the evidence?. Arthritis and Rheumatism, 2005, 52, 2237-2242.	6.7	22
192	A 70-Year-Old Man With Pulmonary Infiltrates and a Positive Antineutrophil Cytoplasmic Autoantibody Test Result. Chest, 2005, 127, 1045-1050.	0.4	11
193	BAFF is elevated in serum of patients with Wegener's granulomatosis. Journal of Autoimmunity, 2005, 25, 298-302.	3.0	137
194	Differences between human proteinase 3 and neutrophil elastase and their murine homologues are relevant for murine model experiments. FEBS Letters, 2005, 579, 5305-5312.	1.3	53
195	Echocardiographic Findings in Patients With Wegener Granulomatosis. Mayo Clinic Proceedings, 2005, 80, 1435-1440.	1.4	75
196	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. Journal of Rheumatology, 2005, 32, 2488-95.	1.0	32
197	Pulmonary Capillaritis. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 547-555.	0.8	21
198	Wegener's granulomatosis presenting as multiple bilateral renal masses. Nephrology Dialysis Transplantation, 2004, 19, 984-987.	0.4	18

#	ARTICLE	IF	CITATIONS
199	Tumor necrosis factor $\gamma$ blockade as therapy for sarcoidosis: Comment on the article by Ulbricht et al. <i>Arthritis and Rheumatism</i> , 2004, 50, 2717-2718.	6.7	0
200	Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2954-2965.	6.7	203
201	Pulmonary $\alpha$ 1-Henoch-Schleien Purpura. <i>Mayo Clinic Proceedings</i> , 2004, 79, 1151-1157.	1.4	34
202	Echocardiographic features of atrial myocarditis with giant cells: A case report. <i>Journal of the American Society of Echocardiography</i> , 2004, 17, 1073-1076.	1.2	10
203	Pulmonary Involvement in Henoch-Schleien Purpura. <i>Mayo Clinic Proceedings</i> , 2004, 79, 1151-1157.	1.4	87
204	Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener) Tj ETQq0 0 0 rgBT/Overlock.10 Tf 50	0.6	217
205	Clinical utility of ANCA tests for the dermatologist. <i>International Journal of Dermatology</i> , 2003, 42, 859-869.	0.5	21
206	Effects of carboxy-terminal modifications of proteinase 3 (PR3) on the recognition by PR3-ANCA. <i>Kidney International</i> , 2003, 63, 756-760.	2.6	24
207	Churg-Strauss syndrome. <i>American Journal of Medicine</i> , 2003, 115, 284-290.	0.6	282
208	Different gender-associated genotype risks of Wegener's granulomatosis and microscopic polyangiitis. <i>Clinical Immunology</i> , 2003, 109, 330-337.	1.4	43
209	Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis. <i>Chest</i> , 2003, 124, 177-185.	0.4	383
210	Sinonasal Osteocartilaginous Necrosis in Cocaine Abusers: Experience in 25 Patients. <i>American Journal of Rhinology &amp; Allergy</i> , 2003, 17, 33-43.	2.3	76
211	Does infection play a role in the pathogenesis of pulmonary vasculitis?. <i>Seminars in Respiratory Infections</i> , 2003, 18, 17-22.	1.3	29
212	Sinonasal osteocartilaginous necrosis in cocaine abusers: experience in 25 patients. <i>American Journal of Rhinology &amp; Allergy</i> , 2003, 17, 33-43.	2.3	14
213	Detection of Anti-Neutrophil Cytoplasmic Antibodies under Actual Clinical Testing Conditions. <i>Clinical Immunology</i> , 2002, 103, 196-203.	1.4	77
214	Long-Term Follow-up of Repair of External Nasal Deformities in Patients With Wegener's Granulomatosis. <i>Laryngoscope</i> , 2002, 112, 731-737.	1.1	46
215	ANCA subsets: influence on disease phenotype.. <i>Cleveland Clinic Journal of Medicine</i> , 2002, 69, SII56-SII56.	0.6	9
216	Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. <i>Journal of Rheumatology</i> , 2002, 29, 309-16.	1.0	87

#	ARTICLE	IF	CITATIONS
217	ARE ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES PATHOGENIC?. Rheumatic Disease Clinics of North America, 2001, 27, 815-832.	0.8	25
218	Cocaine-Induced Midline Destructive Lesions. Medicine (United States), 2001, 80, 391-404.	0.4	138
219	Diffuse alveolar hemorrhage syndromes. Current Opinion in Rheumatology, 2001, 13, 12-17.	2.0	147
220	Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. Arthritis and Rheumatism, 2001, 44, 463-468.	6.7	62
221	A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score. Arthritis and Rheumatism, 2001, 44, 912-920.	6.7	400
222	Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis and Rheumatism, 2001, 44, 2836-2840.	6.7	362
223	Are animal models of vasculitis suitable tools?. Current Opinion in Rheumatology, 2000, 12, 11-19.	2.0	19
224	Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. Journal of Immunological Methods, 2000, 244, 117-131.	0.6	24
225	What you should know about PR3-ANCA. Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA. Arthritis Research, 2000, 2, 263.	2.0	27
226	Meningeal Involvement in Wegener Granulomatosis. Mayo Clinic Proceedings, 2000, 75, 856-859.	1.4	33
227	Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunocomplexes. Journal of Immunological Methods, 1998, 211, 111-123.	0.6	74
228	Antineutrophil cytoplasmic antibodies. Arthritis and Rheumatism, 1998, 41, 1521-1537.	6.7	404
229	Cloning and functional expression of the murine homologue of proteinase 3: implications for the design of murine models of vasculitis. FEBS Letters, 1997, 408, 187-190.	1.3	41
230	Recombinant human proteinase 3, the Wegener's autoantigen, expressed in HMC-1 cells is enzymatically active and recognized by c-ANCA. FEBS Letters, 1996, 390, 265-270.	1.3	46
231	Microtiter plate immunoassay for the evaluation of platelet adhesion to fibronectin. Journal of Immunological Methods, 1996, 191, 55-63.	0.6	7
232	Wegener's Granulomatosis and Pulmonary Vasculitis. Clinical Pulmonary Medicine, 1995, 2, 267-275.	0.3	0
233	Immunohistochemical localization of collagen VI in diabetic glomeruli. Kidney International, 1994, 45, 1648-1656.	2.6	59
234	Recombinant expression and properties of the Kunitz-type protease-inhibitor module from human type VI collagen alpha3(VI) chain. FEBS Journal, 1994, 225, 573-580.	0.2	46

#	ARTICLE	IF	CITATIONS
235	Cutaneous Wegener's granulomatosis: Clinical, histopathologic, and immunopathologic features of thirty patients. <i>Journal of the American Academy of Dermatology</i> , 1994, 31, 605-612.	0.6	203
236	Anti-Neutrophil Cytoplasmic Antibodies. <i>Mayo Clinic Proceedings</i> , 1994, 69, 1197-1198.	1.4	52
237	Lesions of the Respiratory Tract Associated With the Finding of Anti-Neutrophil Cytoplasmic Autoantibodies With a Perinuclear Staining Pattern. <i>Mayo Clinic Proceedings</i> , 1994, 69, 819-824.	1.4	20
238	Expression of Type VI Collagen mRNA During Wound Healing. <i>Journal of Investigative Dermatology</i> , 1993, 100, 329-334.	0.3	65
239	Integrin and Arg-Gly-Asp Dependence of Cell Adhesion to the Native and Unfolded Triple Helix of Collagen Type VI. <i>Experimental Cell Research</i> , 1993, 206, 167-176.	1.2	204
240	Cell adhesion to type-VI collagen. <i>Biochemical Society Transactions</i> , 1991, 19, 843-847.	1.6	36
241	Bronchoalveolar Lavage Fluid Angiotensin-converting Enzyme in Interstitial Lung Diseases. <i>The American Review of Respiratory Disease</i> , 1990, 141, 117-123.	2.9	73
242	Clinical role of C-ANCA testing. <i>Clinical Immunology Newsletter</i> , 1990, 10, 171-174.	0.1	0
243	Role of Testing for Anticytoplasmic Autoantibodies in the Differential Diagnosis of Scleritis and Orbital Pseudotumor. <i>Mayo Clinic Proceedings</i> , 1990, 65, 1110-1117.	1.4	37
244	Anticytoplasmic Autoantibodies in the Diagnosis and Follow-Up of Wegener's Granulomatosis. <i>Mayo Clinic Proceedings</i> , 1989, 64, 28-36.	1.4	272
245	Granulomatosis with Polyangiitis (Wegener's). , 0, , 238-251.		3